Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Tharisa (DI) (THS) by Hot Stock Rockets in ShareProphets
- Buy Victrex plc (VCT) by Tom Winnifrith in ShareProphets
- Buy Victrex plc (VCT) by Steve Moore in ShareProphets
- Buy SSE (SSE) by Bank of America
- Buy National Grid (NG.) by Bank of America
- Buy Wise Class A (WISE) by Bank of America
- Buy Sage Group (SGE) by Bank of America
- Add NATWEST GROUP (NWG) by Simon Watkins in The Motley Fool
- Buy SSP Group (SSPG) by Bank of America
- Buy Kainos Group (KNOS) by Bank of America
- Buy British American Tobacco (BATS) by Simon Watkins in The Motley Fool
- Buy Taylor Wimpey (TW.) by Citi
- Neutral Vistry Group (VTY) by Citi
- Buy Barratt Redrow (BTRW) by Citi
- Buy Bellway (BWY) by Citi
- Neutral Berkeley Group Holdings (The) (BKG) by Citi
- Buy Persimmon (PSN) by Citi
- Buy Whitbread (WTB) by UBS
- Buy Compass Group (CPG) by UBS
- Neutral SSP Group (SSPG) by UBS
Immupharma (IMM) Share Price
Health Care Sector
NOTE: This is based on 9 open tips for Immupharma (IMM)
| Latest Bid : 6.44p | Latest Ask : 7.28p |
| High Today : 7.28p | Low Today : 5.98p |
| This Years High : 17.60p | This Years Low : 1.10p |
| Volume : 3,150,365 | MKT Cap : £30.28M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Immupharma (IMM) Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.Immupharma (IMM) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Avoid | Steve Moore | Premium Only | 2025-02-13 16:05:00 13/02/2025 | -90.08% |
| Avoid | Steve Moore | Premium Only | 2025-01-09 15:35:00 09/01/2025 | -114.12% |
| Buy | Northland Capital | Premium Only | 2018-04-17 16:35:00 17/04/2018 | -60.41% |
| Risky Buy | Paul Summers | Premium Only | 2018-03-01 09:50:00 01/03/2018 | -92.31% |
| Buy | FinnCap | Premium Only | 2017-12-21 11:30:00 21/12/2017 | -91.87% |
Immupharma (IMM) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 6.44p | Latest Ask : 7.28p |
| High Today : 7.28p | Low Today : 5.98p |
| This Years High : 17.60p | This Years Low : 1.10p |
| Volume : 3,150,365 | MKT Cap : £30.28M |
Immupharma Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Immupharma Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Avoid | Steve Moore | Premium Only | 2025-02-13 16:05:00 13/02/2025 | -90.08% |
| Avoid | Steve Moore | Premium Only | 2025-01-09 15:35:00 09/01/2025 | -114.12% |
| Buy | Northland Capital | Premium Only | 2018-04-17 16:35:00 17/04/2018 | -60.41% |
| Risky Buy | Paul Summers | Premium Only | 2018-03-01 09:50:00 01/03/2018 | -92.31% |
| Buy | FinnCap | Premium Only | 2017-12-21 11:30:00 21/12/2017 | -91.87% |